Table 2.
Univariate, multivariate Cox models regarding DFS, OS, BCSS.
| Disease-Free Survival | ||||
|---|---|---|---|---|
| Univariate Model HR (95% CI) | p Value | Multivariate Model HR (95% CI) | p Value | |
| HER2 status (0 vs. low) | 0.793 (0.659–0.953) | 0.014 | 0.745 (0.594–0.933) | 0.010 |
| Menopause (Pre vs. Post) | 0.769 (0.628–0.941) | 0.011 | 0.884 (0.697–1.120) | 0.307 |
| BRCA1/2 mutation (no vs. yes) | 2.404 (1.461–3.956) | <0.001 | 3.023 (1.721–5.308) | <0.001 |
| Breast Surgery (BCS vs. TM) | 2.198 (1.843–2.622) | <0.001 | 0.703 (0.493–1.005) | 0.053 |
| Axilla Surgery | 2.651 (2.214–3.174) | <0.001 | 1.067 (0.772–1.474) | 0.694 |
| Chemotherapy (no vs. yes) | 1.493 (1.244–1.791) | <0.001 | 0.651 (0.486–0.873) | 0.004 |
| Radiation therapy (yes vs. no) | 1.547 (1.270–1.885) | <0.001 | 2.776 (1.901–4.055) | <0.001 |
| pT stage | 2.130 (1.871–2.425) | <0.001 | 1.720 (1.424–2.078) | <0.001 |
| pN stage | 1.785 (1.622–1.963) | <0.001 | 1.563 (1.313–1.861) | <0.001 |
| Histologic grade | 2.071 (1.808–2.371) | <0.001 | 2.008 (1.526–2.642) | <0.001 |
| Nuclear grade | 1.797 (1.546–2.090) | <0.001 | 0.859 (0.641–1.153) | 0.311 |
| Ki-67 (<20% vs. >20%) | 2.119 (1.738–2.584) | <0.001 | 1.247 (0.982–1.583) | 0.070 |
| Overall Survival | ||||
| HER2 status (0 vs. low) | 0.730 (0.560–0.952) | 0.02 | 0.630 (0.447–0.887) | 0.008 |
| Menopause (Pre vs. Post) | 1.998 (1.554–2.569) | <0.001 | 2.362 (1.728–3.230) | <0.001 |
| BRCA1/2 mutation (no vs. yes) | 1.678 (0.746–3.772) | 0.21 | 3.300 (1.333–8.172) | 0.01 |
| Breast Surgery (BCS vs. TM) | 2.724 (2.126–3.490) | <0.001 | 0.800 (0.502–1.273) | 0.346 |
| Axilla Surgery | 4.214 (3.192–5.564) | <0.001 | 2.091 (1.290–3.389) | 0.003 |
| Chemotherapy (no vs. yes) | 1.235 (0.954–1.597) | 0.109 | 0.373 (0.247–0.562) | <0.001 |
| Radiation therapy (yes vs. no) | 1.675 (1.270–2.208) | <0.001 | 2.534 (1.535–4.181) | <0.001 |
| pT stage | 2.636 (2.220–3.131) | <0.001 | 2.100 (1.619–2.723) | <0.001 |
| pN stage | 2.053 (1.812–2.326) | <0.001 | 1.541 (1.216–1.952) | <0.001 |
| Histologic grade | 1.995 (1.655–2.406) | <0.001 | 1.269 (0.869–1.855) | 0.217 |
| Nuclear grade | 2.052 (1.669–2.523) | <0.001 | 1.171 (0.786–1.746) | 0.437 |
| Ki-67 (<20% vs. >20%) | 2.115 (1.595–2.805) | <0.001 | 1.407 (0.990–1.999) | 0.057 |
| BC-Specific Survival | ||||
| HER2 status (0 vs. low) | 0.553 (0.344–0.889) | 0.014 | 0.462 (0.249–0.857) | 0.014 |
| Menopause (Pre vs. Post) | 1.307 (0.848–2.016) | 0.225 | 1.527 (0.888–2.628) | 0.126 |
| BRCA1/2 mutation (no vs. yes) | 2.396 (0.757–7.577) | 0.137 | 2.870 (0.678–12.143) | 0.152 |
| Breast Surgery (BCS vs. TM) | 3.569 (2.336–5.453) | <0.001 | 0.848 (0.402–1.787) | 0.664 |
| Axilla Surgery | 9.065 (5.026–16.350) | <0.001 | 2.378 (0.964–5.864) | 0.06 |
| Chemotherapy (no vs. yes) | 3.082 (1.860–5.104) | <0.001 | 1.495 (0.534–4.183) | 0.444 |
| Radiation therapy (yes vs. no) | 1.181 (0.717–1.947) | 0.514 | 2.552 (1.091–5.970) | 0.031 |
| pT stage | 4.355 (3.309–5.732) | <0.001 | 3.060 (2.009–4.661) | <0.001 |
| pN stage | 2.576 (2.094–3.169) | <0.001 | 1.326 (0.912–1.928) | 0.139 |
| Histologic grade | 3.238 (2.349–4.463) | <0.001 | 2.107 (1.103–4.027) | 0.024 |
| Nuclear grade | 3.395 (2.384–4.835) | <0.001 | 1.188 (0.597–2.364) | 0.623 |
| Ki-67 (<20% vs. >20%) | 3.457 (2.148–5.562) | <0.001 | 1.444 (0.817–2.552) | 0.206 |
Abbreviations: DFS, disease-free survival; OS, overall survival; BCSS, breast cancer-specific survival; BCS, breast conserving surgery; TM, total mastectomy.